Comprehensive Translational Medicine
CDO Enabling Drug R&D
A Leader of Companion Diagnostics Total-Solution Providers
Patient Testing for Precision Medicine
State-of-Art Facilities & Global-standard Quality Systems
Translational Medicine
MEDx Translational Medicine Co., Ltd (simply MEDx) was founded in 2013, formerly known as QIAGEN (Suzhou) Translational Medicine Co., Ltd.Obtained with comprehensive technology platforms, high quality system, and strong IVD R&D experience, MEDx has become a leading innovative company in companion diagnostics and the total solution provider for precision medicine in China.
Taking advantage of the comprehensive translational platforms including genomics, proteomics, cytomics, and pathology, MEDx offers integrated solutions from biomarker discovery, target validation, molecular testing, and patient stratification for drug clinical trials, to the IVD/CDx R&D and commercialization. With a world-class technical team and a rich IVD/CDx pipeline, MEDx collaborates with hundreds of world-renowned pharmaceutical companies.
We are honored to invite you to participate in the Medlab Asia & Asia Health, which will take
Time:5-8 February, 2024Address:Dubai World Trade CentreMEDx Booth No: # Z2.H19We are honored
Introduction The study of cancer has been extended from single genes to macrogenes, and from sing
view more >>
view more >>
view more >>
view more >>
A combination of Amgen’s monoclonal antibody bemarituzumab and chemotherapy improved overall surviv
Pfizer has terminated a Phase II trial that was evaluating its investigational fusion protein maplir
FDA leaders Marty Makary and Vinay Prasad have struck a tone of urgency when it comes to bringing in
Acute myeloid leukemia (AML) is an aggressive cancer affecting the blood and bone marrow that progre
A study led by clinician-scientists and researchers at the National Cancer Centre Singapore (NCCS) h
A University of Alberta research team has identified a DNA structure that activates the immune syste
Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene—a gene that c
Research led by Samsung Medical Center finds breast cancer survivors exhibit an 8% lower risk of Alz